Rating Change
Goldman Sachs analysts initiated coverage on Zoetis Inc. (NYSE:ZTS) with a rating of Neutral on October 16, 2026.
Goldman Sachs analysts initiated coverage on Zoetis Inc. (NYSE:ZTS) with a rating of Neutral on October 16, 2026.

At publication ·
Zoetis Inc. (NYSE:ZTS) · new coverage
At a glance
Goldman Sachs analysts initiated coverage on Zoetis Inc. (NYSE:ZTS) with a rating of Neutral on October 16, 2026.
Zoetis Inc. operates in the Healthcare sector. The stock currently trades at $79.32 with a market capitalization of $51.8B. The stock has declined 37.0% over the past 52 weeks.
Analyst coverage from Goldman Sachs provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zoetis Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | Goldman Sachs | Neutral | N/A |
| Aug 25, 2026 | TD Cowen | Buy | N/A |
| Aug 20, 2026 | Stifel | Hold | N/A |
| Aug 11, 2026 | Citigroup | Buy | N/A |
| Aug 11, 2026 | BNP Paribas | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ZTS Stock Page
A rating of Neutral from Goldman Sachs reflects the analyst's outlook on Zoetis Inc. (NYSE:ZTS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZTS forecast page.
Current market data
NYSE · ZTS
$79.72
Up: +$1.45 · +1.85%
Live quote updated
Keep reading